MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication
Clinical Scorecard: MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
At a Glance
| Category | Detail |
|---|
| Condition | Metastatic Neuroendocrine Tumors (NETs) |
| Key Mechanisms | SurVaxM is a peptide vaccine targeting the protein survivin, which may block tumor growth and elicit an immune response. |
| Target Population | Patients with progressing metastatic neuroendocrine tumors. |
| Care Setting | Roswell Park Comprehensive Cancer Center, Buffalo, New York. |
Key Highlights
- Phase 2 trial evaluates SurVaxM combined with temozolomide versus temozolomide alone.
- SurVaxM has shown safety and immune response in prior phase 1 trials.
- Approximately 52% of NET specimens express survivin, correlating with aggressive tumor behavior.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of NETs based on clinical evaluation and imaging studies.
Management
- Consideration of SurVaxM in combination with temozolomide for patients progressing on first-line therapy.
Monitoring & Follow-up
- Monitor for immune responses and clinical benefits in patients receiving SurVaxM.
Risks
- Potential adverse effects associated with immunotherapy and chemotherapy.
Patient & Prescribing Data
Patients diagnosed with metastatic neuroendocrine tumors.
SurVaxM may provide a new treatment option for patients with limited options after first-line therapy.
Clinical Best Practices
- Engage in collaborative research to explore new treatment options for NETs.
- Utilize immunotherapy approaches targeting survivin in eligible patients.
Related Resources & Content
